Management of Elevated Globulin and Total Protein

Initial Diagnostic Evaluation

• The International Myeloma Society recommends obtaining a complete blood count with differential to assess for cytopenias that may suggest bone marrow involvement, and measuring serum creatinine, blood urea nitrogen, calcium, and electrolytes to evaluate for end-organ damage 1
• The American Association for the Study of Liver Diseases suggests ordering liver function tests including ALT, AST, alkaline phosphatase, and bilirubin to assess for liver disease 2, 3
• The European Hematology Association recommends performing serum protein electrophoresis (SPEP) and immunofixation to identify monoclonal proteins, and measuring quantitative immunoglobulins (IgG, IgA, and IgM) to characterize the nature of the elevated globulins 1
• The National Comprehensive Cancer Network advises ordering serum free light chain assay to detect light chain production, and considering 24-hour urine collection for protein electrophoresis and immunofixation to detect Bence Jones proteinuria 1, 4

Further Evaluation Based on Initial Results

• The American Society of Hematology recommends performing bone marrow aspiration and biopsy with immunophenotyping to assess plasma cell percentage and clonality if a monoclonal protein is detected 4, 1
• The International Myeloma Working Group suggests ordering skeletal survey or more advanced imaging (MRI of spine and pelvis) to detect bone lesions, and considering cytogenetic analysis and FISH studies on bone marrow samples to assess for high-risk features 4, 5
• The Infectious Diseases Society of America recommends screening for chronic infections (viral hepatitis, HIV) if a polyclonal gammopathy is detected 2, 6

Management Based on Underlying Cause

• The National Comprehensive Cancer Network advises referring patients with multiple myeloma, Waldenström macroglobulinemia, or other plasma cell dyscrasia to hematology/oncology for specific treatment, and implementing risk-stratified monitoring based on the Mayo Clinic risk stratification model for MGUS patients 4, 1
• The American College of Physicians recommends treating the underlying cause (infection, inflammatory condition, liver disease) for polyclonal gammopathies, and monitoring globulin levels to assess response to treatment 2, 3

Special Considerations

• The European Hematology Association notes that significantly elevated calculated globulin ≥50 g/L may indicate liver disease, hematological malignancy, autoimmune disease, or infections, and recommends considering hyperviscosity syndrome in patients with very high globulin levels 4, 5
• The American Society of Hematology advises that funduscopic examination is more helpful than laboratory testing in identifying clinically significant hyperviscosity 4, 5

Follow-up Recommendations

• The International Myeloma Working Group recommends following disease-specific protocols for monitoring response in patients with monoclonal gammopathy requiring treatment, and continuing surveillance according to risk stratification for MGUS patients 4, 1
• The National Comprehensive Cancer Network suggests considering repeat protein electrophoresis after treatment of underlying condition to document resolution 1

Pitfalls to Avoid

• The American Society of Hematology advises avoiding unnecessary bone marrow examinations in patients with clear evidence of polyclonal gammopathy due to inflammatory conditions, and remembering that hyperviscosity symptoms correlate poorly with laboratory measurements and require clinical assessment 4, 5